Discover Longevity Biotechnology Association’s latest achievements
Recommendations for biomarker data collection in clinical trials by longevity biotechnology companies (npj Aging 2025)
Biomarkers of aging have the potential to transform geroscience clinical trials because of their broad applications in stratifying participants, prioritizing interventions, and monitoring responses to geroprotectors. As longevity biotechnology companies (LBCs) continue to plan and launch innovative clinical trials, standard practices in collecting data and applying biomarkers of aging will allow the field to support parallel and ongoing validation and benchmarking efforts for aging biomarkers. Moreover, defining best practices will ensure future reuse of valuable clinical data through pre-competitive alignment on shared tools. Here, we propose recommendations for such collections. We believe that wide adoption of these recommendations will allow LBCs to produce and leverage the highest quality data from their clinical trials, while also benefiting the geroscience field more broadly with minimal additional effort.
Can GLP-1Drugs Slow Aging?
Join Nir Barzilai, M.D., Director of the Institute for Aging Research at Albert Einstein College of Medicine, and James Peyer, Ph.D., CEO of Cambrian Bio, for a dynamic debate followed by a LBA members Q&A. Together, they’ll explore GLP-1s, their effects, and their potential to support longer, healthier lives.
EC-Vital: Accelerating Therapeutic Innovation in Aging
Last month’s LBA Roundtable focused on the THRIVE Act—a forward-looking proposal designed to accelerate the development of therapies that promote longer, healthier lives. Co-authored by Dr. Zan Fleming, David Fox, and Thomas Seoh—experts in FDA regulation and biotech—the Act outlines a three-tiered regulatory framework to support innovative healthspan interventions. It also offers key incentives, such as FDA-led guidance and market exclusivity, to encourage development in this space. The discussion examined how the THRIVE Act could shape the future of aging research and move healthcare toward a more proactive, prevention-focused model.
Roundtable with Alex Colville of AGE1: Revolutionizing Global Healthcare
The Longevity Biotechnology Association gathered for an exclusive roundtable discussion hosted by LBA co-founder James Peyer, featuring special guest Alex Colville, Managing Partner at AGE1. Together, they explored how AGE1 is revolutionizing global healthcare by investing in bold, science-driven technologies aimed at extending human healthspan. From breakthrough biotech to scalable healthcare solutions, the conversation tackled how strategic investment and translational science are converging to redefine aging—and the future of health itself. Alex also shared AGE1’s unique approach to supporting early-stage companies with high-impact potential. “We’re not just funding companies — we’re shaping a future where age-related decline is optional,” said Colville. Stay tuned for more from LBA’s roundtable series as we continue to spotlight visionary leaders driving the longevity revolution.
XPRIZE Healthspan: Everything You Wanted to Know
The LBA is excited to introduce Jamie Justice, Ph.D., Executive Vice President of the Health Domain at the XPRIZE Foundation, in conversation with LBA Co-Founder James Peyer, PhD. Jaimi has traveled the world promoting the XPRIZE Healthspan, resulting in 431 teams from 53 countries signing up to compete. In this video, James and Jaimi dive into key questions like: How has the XPRIZE Healthspan been shaped to align with biotic companies' goals, especially those working on longevity and related advancements? How can we best collaborate with XPRIZE, and what are the opportunities for community-driven biomarker development? Plus, hear about the exciting milestones ahead as teams prepare to compete in this global challenge aimed at extending healthy human lifespans. Tune in for insights into the XPRIZE journey and what's coming next!
Four FDA-approved drugs decrease overall mortality in humans – interview with Dr. Nir Barzilai
Ahead of his appearance at Longevity Investors Conference, Nir Barzilai talks gerotherapeutics and choosing the right drugs for aging in this Longevity.Technology podcast.
Phil Newman: Longevity Biotechnology Investing
Join Phil Newman, CEO & Founder of Longevity.Technology, a digital investment platform for international investors and longevity start-ups, as he sits down at the LBA roundtable with Nir Barzilai for a presentation on Longevity Biotechnology Investing.
Blockbuster Statin Market Foundations and Their Implications for Longevity Biotech Therapeutics
Join LBA members James Peyer and Nir Barzilai in an insightful discussion with Jerry McLaughlin, CEO of Life Biosciences. Learn from Jerry's extensive experience in senior leadership roles at pharmaceutical companies and his involvement in the development of statins. Discover valuable lessons for geroscience therapeutics as we venture into clinical trials, and gain insights from Jerry's wealth of knowledge.
Hevolution's Bill Greene: Spotlight On Investing
Dr. William (Bill) Greene, Chief Investment Officer at Hevolution, joins Jim Mellon, LBA Co-Founder, at the LBA roundtable to shed light on Hevolution's investment strategy. During their roundtable discussion, Dr. Greene will address queries about investment decision-making, budget, portfolio diversification, and their envisioned accomplishments through strategic investing over the next five years.
Defining a Longevity Biotechnology Company (Nature Biotechnology, vol. 41)
Because longevity biotechnology represents a paradigm shift in therapeutic approach and faces unique challenges from the standpoint of clinical development, path to approval and patient population, it makes sense to define this rapidly advancing field and articulate standards that identify its bona fide constituents. The Longevity Biotechnology Association (LBA) is a non-profit organization created to foster collaboration, propose guidelines for industry, educate stakeholders and translate geroscience to prevent the diseases associated with aging and extend healthspan.
The Connection between healthy aging, drug development and psychedelics
Nir Barzilai and Christian Angermayer of Apeiron Investment Group discuss the connection between healthy aging, drug development and psychedelics at the LBA roundtable.
Targeting aging to prevent diseases – interview with Dr. Nir Barzilai
An interview Dr. Nir Barzilai, a renowned geroscientist and quadraScope's scientific advisor. Among various topics, we covered the mission of two new longevity-focused organizations: the Longevity Biotechnology Association and the Healthy Longevity Medicine Society. We also discussed the impact of the Targeting Aging with Metformin (TAME) trial and key discoveries made by the SuperAgers initiative.
No more ‘playing God’: How the longevity field is trying to recast its work as serious science (via Stat+)
LBA January 2023 Roundtable: Insights into the Gerotherapeutics Roadmap with Michael Ringel
Nir Barzilai and Michael Ringel of Boston Consulting Group discuss how to move the geroscience field forward.
LBA Racing to a Longevity Trial
Celine Halioua CEO of Loyal/Cellular Longevity talks to James Peyer CEO of Cambrian Bio about Loyal's approach to longevity clinical trials.
Longevity dividends: How to frame the concept and engage with people of influence
Longevity Biotechnology Association features Jim Mellon and Andrew Scott for our October Roundtable.
Should Aging Be Called A Disease?
The LBA presents members Drs. Nir Barzilai and David Sinclair discussing whether aging should be classified as a disease and the associated pros and cons.
"Age is just a number – and that number is $33trn" - Via AGBI
As companies join the global race to prolong life, the Gulf is positioned to lead the way in preventative medicine.